How should I manage a patient presenting with supraventricular tachycardia following cannabis ingestion?

Management of Supraventricular Tachycardia Post-Cannabis Ingestion

Manage this patient using the standard ACC/AHA/HRS SVT treatment algorithm—the cannabis ingestion does not change your acute management approach. 1

Immediate Assessment and First-Line Treatment

Hemodynamic Status Determines Your Path

If hemodynamically unstable (hypotension, altered mental status, chest pain, acute heart failure):

• Proceed immediately to synchronized cardioversion 1, 2
• Do not delay for vagal maneuvers or adenosine
• Have defibrillator ready as cardioversion may trigger brief ventricular arrhythmias

If hemodynamically stable, follow this sequence:

Step 1: Vagal Maneuvers (First-Line)

• Perform Valsalva maneuver with patient supine: bear down against closed glottis for 10-30 seconds (equivalent to 30-40 mmHg) 1
• If unsuccessful, attempt carotid sinus massage (after confirming no bruit): apply steady pressure for 5-10 seconds 1
• Alternative: apply ice-cold wet towel to face (diving reflex) 1
• Success rate approximately 28% when switching between techniques 1

Step 2: Adenosine (If Vagal Maneuvers Fail)

• Adenosine 6 mg rapid IV push, followed by 20 mL saline flush 1
• If no response in 1-2 minutes: 12 mg rapid IV push (can repeat once)
• 90-95% effective for terminating AVNRT and orthodromic AVRT 1
• Critical caveat: Have cardioversion equipment immediately available—adenosine can precipitate atrial fibrillation with rapid ventricular response or even ventricular fibrillation 1
• Expect brief side effects (flushing, chest discomfort, dyspnea) lasting <1 minute in ~30% of patients 1

Step 3: AV Nodal Blocking Agents (If Adenosine Fails)

For hemodynamically stable patients:

• Diltiazem 0.25 mg/kg IV over 2 minutes (preferred based on comparative data) 1
  • If no response: 0.35 mg/kg IV after 15 minutes
  • Success rate 80-98% 1
• Alternative: Verapamil 5-10 mg IV over 2 minutes 1
• Alternative: IV beta-blockers (esmolol or metoprolol) 1, 2

Critical warning: Slow infusion over 20 minutes to minimize hypotension risk 1. Ensure this is NOT ventricular tachycardia or pre-excited atrial fibrillation before giving calcium channel blockers or beta-blockers, as these can cause hemodynamic collapse or ventricular fibrillation 1.

Step 4: Synchronized Cardioversion (If Pharmacotherapy Fails)

• Perform after adequate sedation/anesthesia in stable patients 1
• Highly effective for terminating all forms of SVT 1

Cannabis-Specific Considerations

What the Evidence Shows About Cannabis and SVT

The research reveals important context but does not alter your acute management:

• Cannabis causes sympathetic stimulation leading to tachycardia, particularly in the first 20 minutes post-use 3
• In healthy cannabis users, heart rate increases initially then declines 4 hours post-use 3
• SVT occurred in 29.7% of healthy cannabis users vs 58.3% in those with ischemic heart disease 3
• Importantly, SVT incidence actually decreased with increased cannabis use frequency in both groups 3
• Cannabis is associated with various arrhythmias, but SVT is not the most concerning—ventricular arrhythmias and cardiac arrest are more worrisome complications 4

Key Clinical Pitfalls to Avoid

1. Do not assume the SVT will self-resolve just because cannabis effects are temporary—treat the arrhythmia definitively 1

2. Screen for underlying cardiac disease: Cannabis-induced SVT may unmask ischemic heart disease, particularly in patients with risk factors 3, 4. Consider troponin and ECG after conversion, especially if patient has chest pain or is >30 years old.

3. Be vigilant for acute coronary syndrome: Cannabis causes coronary vasospasm, endothelial dysfunction, and prothrombotic effects 5, 6. If patient has chest pain or ST-segment changes, treat as potential ACS regardless of age.

4. Watch for recurrent arrhythmias: Patients may have atrial or ventricular premature complexes immediately after conversion that can reinitiate SVT 1. Consider prophylactic antiarrhythmic if this occurs.

5. Do not use AV nodal blockers if pre-excitation (WPW) is present on baseline ECG—this can precipitate ventricular fibrillation if atrial fibrillation develops 1

Post-Conversion Management

After successful conversion:

• Monitor for at least 4-6 hours for recurrence
• Obtain 12-lead ECG to assess for pre-excitation, ischemia, or structural abnormalities
• Consider cardiology consultation for recurrent episodes or if structural heart disease suspected
• Patient education: Counsel on cannabis-arrhythmia association and cardiovascular risks, particularly if underlying cardiac disease or risk factors present 4
• Document substance use history for future reference

Disposition

• Admit if: hemodynamically unstable, required cardioversion, evidence of ACS, recurrent episodes, or significant comorbidities
• Discharge if: successfully converted, hemodynamically stable for 4-6 hours, no evidence of structural heart disease, reliable follow-up arranged
• Arrange cardiology follow-up for consideration of EP study/ablation if recurrent symptomatic episodes 1, 2